Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06802172 · ClinicalTrials.gov registry record · NA

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

A NA study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06802172: Recruiting NA study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Fred Hutchinson Cancer Center.

NCT06802172 is a NA study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 100 participants, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06802172, a NA study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadjuvant treatment at the Alaska Native Medical Center (ANMC), which is part of the Alaska Native Tribal Health Consortium (ANTHC). A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.

Primary Outcome

The pCR will be defined as an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected rectal or breast specimen and all sampled regional lymph nodes. It will be treated as a binary variable.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • BEHAVIORAL Time-restricted eating
  • BEHAVIORAL Health coaching

Study Locations (1)

Alaska

  • Alaska Native Medical Center (ANMC) - Anchorage

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-03-31
Est. Completion 2029-08-31
Phase NA
Fred Hutchinson Cancer Center

483 total trials

What NCT06802172 shows while recruiting

NCT06802172 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower).

The record links to 7 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT06802172 reports a single indexed study location in Alaska.

Frequently Asked Questions

What is clinical trial NCT06802172 about?

NCT06802172 is a clinical study titled "Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial". The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadj...

What is the current status of trial NCT06802172?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-03-31. Estimated completion is 2029-08-31.

What conditions does trial NCT06802172 study?

This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Solid Tumor Cancer, Rectal Cancer Stage II.

What interventions are being tested in trial NCT06802172?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Time-restricted eating (BEHAVIORAL), Health coaching (BEHAVIORAL).

Who is sponsoring clinical trial NCT06802172?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06802172 being conducted?

This trial has 1 study location across Alaska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Stage II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06802172's enrollment target sits among peer trials

100 8th of 22 higher than 13 of 22 other Breast Cancer Stage II trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer Stage II trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06802172, the US trial registry maintained by the National Library of Medicine. NCT06802172 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.